The phase 3 studies differed from the phase 2 study, in dosage (10 mg or 30 mg or 60 mg for phase 3 vs. 30 mg for phase 2), and frequency of the idalopirdine treatment (QD for phase 3 vs. TID for phase 2), background therapy (all cholinesterase inhibitors for phase 3 vs. only donepezil for phase 2), cognitive impairment severity (MMSE12-22, mild to moderate for phase 3 vs. MMSE12-19, moderate for phase 2), and study geography (worldwide for phase 3 vs. Europe, Australia, Czech Republic and Canada for phase 2). The gene discussed is BCHE; the disease is Cognitive impairment.